Funding
This work was supported by the National Natural Science Foundation of
China (No. 81970711, 81670751 and 81000329).
1. Zisser A, Ipsen DH, Tveden-Nyborg P. Hepatic Stellate Cell Activation
and Inactivation in NASH-Fibrosis-Roles as Putative Treatment Targets?
Biomedicines. 2021 Mar 31;9(4):365.
2. Jarvis H, Craig D, Barker R, Spiers G, Stow D, Anstee QM, et al.
Metabolic risk factors and incident advanced liver disease in
non-alcoholic fatty liver disease (NAFLD): A systematic review and
meta-analysis of population-based observational studies. PLoS Med. 2020
Apr;17(4):e1003100.
3. Chung W, Promrat K, Wands J. Clinical implications, diagnosis, and
management of diabetes in patients with chronic liver diseases. World J
Hepatol. 2020 Sep 27;12(9):533–57.
4. Manilla V, Santopaolo F, Gasbarrini A, Ponziani FR. Type 2 Diabetes
Mellitus and Liver Disease: Across the Gut-Liver Axis from Fibrosis to
Cancer. Nutrients. 2023 May 29;15(11):2521.
5. Long MT, Noureddin M, Lim JK. AGA Clinical Practice Update: Diagnosis
and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals:
Expert Review. Gastroenterology. 2022 Sep;163(3):764-774.e1.
6. Danne T, Garg S, Peters AL, Buse JB, Mathieu C, Pettus JH, et al.
International Consensus on Risk Management of Diabetic Ketoacidosis in
Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter
(SGLT) Inhibitors. Diabetes Care. 2019 Jun;42(6):1147–54.
7. Zhou P, Tan Y, Hao Z, Xu W, Zhou X, Yu J. Effects of SGLT2 inhibitors
on hepatic fibrosis and steatosis: A systematic review and
meta-analysis. Front Endocrinol (Lausanne). 2023;14:1144838.
8. Zhao DM, Li CQ, Sun YM, Fan JY, Wu N, Sun YN, et al. Sodium glucose
cotransporter-2-inhibitor dapagliflozin improves nonalcoholic fatty
liver disease by ameliorating dipeptidyl-peptidase-4 protein expression
in diabetic mice. Endokrynol Pol. 2023;74(2):190–6.
9. Takahashi H, Kessoku T, Kawanaka M, Nonaka M, Hyogo H, Fujii H, et
al. Ipragliflozin Improves the Hepatic Outcomes of Patients With
Diabetes with NAFLD. Hepatol Commun. 2022 Jan;6(1):120–32.
10. Arai T, Atsukawa M, Tsubota A, Mikami S, Ono H, Kawano T, et al.
Effect of sodium-glucose cotransporter 2 inhibitor in patients with
non-alcoholic fatty liver disease and type 2 diabetes mellitus: a
propensity score-matched analysis of real-world data. Ther Adv
Endocrinol Metab. 2021;12:20420188211000244.
11. Taheri H, Malek M, Ismail-Beigi F, Zamani F, Sohrabi M, Reza Babaei
M, et al. Effect of Empagliflozin on Liver Steatosis and Fibrosis in
Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A
Randomized, Double-Blind, Placebo-Controlled Trial. Adv Ther. 2020
Nov;37(11):4697–708.
12. Hata S, Okamura T, Kobayashi A, Bamba R, Miyoshi T, Nakajima H, et
al. Gut Microbiota Changes by an SGLT2 Inhibitor, Luseogliflozin, Alters
Metabolites Compared with Those in a Low Carbohydrate Diet in db/db
Mice. Nutrients. 2022 Aug 27;14(17):3531.
13. Lecamwasam A, Ekinci EI. Novel Associations of Empagliflozin on the
Gut Microbiome and Metabolome in Type 2 Diabetes. J Clin Endocrinol
Metab. 2022 Sep 28;107(10):e4246–7.
14. Hao H, Li Z, Qiao SY, Qi Y, Xu XY, Si JY, et al. Empagliflozin
ameliorates atherosclerosis via regulating the intestinal flora.
Atherosclerosis. 2023 Apr;371:32–40.
15. Deng L, Yang Y, Xu G. Empagliflozin ameliorates type 2 diabetes
mellitus-related diabetic nephropathy via altering the gut microbiota.
Biochim Biophys Acta Mol Cell Biol Lipids. 2022 Dec;1867(12):159234.
16. Yao Q, Yu Z, Meng Q, Chen J, Liu Y, Song W, et al. The role of small
intestinal bacterial overgrowth in obesity and its related diseases.
Biochem Pharmacol. 2023 Jun;212:115546.
17. Qin J, Ling X, Wang Q, Huang Z, Guo B, Zhang C, et al. Integrated
Gut Microbiota and Urine Metabolite Analyses of T2DM with NAFLD Rat
Model. Appl Biochem Biotechnol. 2023 Mar 4;
18. Xu J, Lv H. PSTPIP2 alleviates obesity associated adipose tissue
inflammation and insulin resistance in diabetes mice through promoting
M2 macrophage polarization via activation of PPARγ. J Diabetes
Complications. 2023 Jun;37(6):108479.
19. Jonker AM, Dijkhuis FW, Boes A, Hardonk MJ, Grond J.
Immunohistochemical study of extracellular matrix in acute galactosamine
hepatitis in rats. Hepatology. 1992 Mar;15(3):423–31.
20. Jiang Y, Zhu L, Wu D, Ni Y, Huang C, Ye H, et al. Type IIB PKA is
highly expressed in β cells and controls cell proliferation via
regulating Cyclin D1 expression. FEBS J. 2022 May;289(10):2865–76.
21. Li L, Li Q, Huang W, Han Y, Tan H, An M, et al. Dapagliflozin
Alleviates Hepatic Steatosis by Restoring Autophagy via the AMPK-mTOR
Pathway. Front Pharmacol. 2021;12:589273.
22. Delgado TC, de Las Heras J, Martínez-Chantar ML. Understanding
gut-liver axis nitrogen metabolism in Fatty Liver Disease. Front
Endocrinol (Lausanne). 2022;13:1058101.
23. ElBaset MA, Salem RS, Ayman F, Ayman N, Shaban N, Afifi SM, et al.
Effect of Empagliflozin on Thioacetamide-Induced Liver Injury in Rats:
Role of AMPK/SIRT-1/HIF-1α Pathway in Halting Liver Fibrosis.
Antioxidants (Basel). 2022 Oct 30;11(11):2152.
24. Bischoff SC, Ockenga J, Eshraghian A, Barazzoni R, Busetto L,
Campmans-Kuijpers M, et al. Practical guideline on obesity care in
patients with gastrointestinal and liver diseases - Joint ESPEN/UEG
guideline. Clin Nutr. 2023 Apr 10;42(6):987–1024.
25. Gairing SJ, Schleicher EM, Labenz C. Diabetes mellitus - risk factor
and potential future target for hepatic encephalopathy in patients with
liver cirrhosis? Metab Brain Dis. 2023 Jun;38(5):1691–700.
26. Scheen AJ. Beneficial effects of SGLT2 inhibitors on fatty liver in
type 2 diabetes: A common comorbidity associated with severe
complications. Diabetes Metab. 2019 Jun;45(3):213–23.
27. Meng Z, Liu X, Li T, Fang T, Cheng Y, Han L, et al. The SGLT2
inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated
inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy
pathway. Int Immunopharmacol. 2021 May;94:107492.
28. Wu J, Chen Y, Yang H, Gu L, Ni Z, Mou S, et al. Sodium glucose
co-transporter 2 (SGLT2) inhibition via dapagliflozin improves diabetic
kidney disease (DKD) over time associatied with increasing effect on the
gut microbiota in db/db mice. Front Endocrinol (Lausanne).
2023;14:1026040.
29. Li Z, Dong J, Wang M, Yan J, Hu Y, Liu Y, et al. Resveratrol
ameliorates liver fibrosis induced by nonpathogenic Staphylococcus in
BALB/c mice through inhibiting its growth. Mol Med. 2022 May 4;28(1):52.
30. Ohtani N, Kawada N. Role of the Gut-Liver Axis in Liver
Inflammation, Fibrosis, and Cancer: A Special Focus on the Gut
Microbiota Relationship. Hepatol Commun. 2019 Apr;3(4):456–70.
31. Kabiri-Arani S, Motallebi M, Taheri MA, Kheiripour N, Ardjmand A,
Aghadavod E, et al. The Effect of Heat-Killed Lactobacillus plantarum on
Oxidative Stress and Liver Damage in Rats with Bile Duct
Ligation-Induced Hepatic Fibrosis. Probiotics Antimicrob Proteins. 2022
Dec 16;
32. Liu Y, Chen K, Li F, Gu Z, Liu Q, He L, et al. Probiotic
Lactobacillus rhamnosus GG Prevents Liver Fibrosis Through Inhibiting
Hepatic Bile Acid Synthesis and Enhancing Bile Acid Excretion in Mice.
Hepatology. 2020 Jun;71(6):2050–66.
33. Chi X, Cheng DY, Sun X, Liu SA, Wang RB, Chen Q, et al. Efficacy of
Biejiajian Pill on Intestinal Microbiota in Patients with Hepatitis B
Cirrhosis/Liver Fibrosis: A Randomized Double-Blind Controlled Trial.
Chin J Integr Med. 2023 May 24;
34. Henke MT, Kenny DJ, Cassilly CD, Vlamakis H, Xavier RJ, Clardy J.
Ruminococcus gnavus, a member of the human gut microbiome associated
with Crohn’s disease, produces an inflammatory polysaccharide. Proc Natl
Acad Sci U S A. 2019 Jun 25;116(26):12672–7.
35. Wang X, Hao W, Huang X, Duan Z. Lower blood lipid level from the
administration of plant tannins via altering the gut microbiota
diversity and structure. Food Funct. 2023 May 22;14(10):4847–58.
36. Braunersreuther V, Viviani GL, Mach F, Montecucco F. Role of
cytokines and chemokines in non-alcoholic fatty liver disease. World J
Gastroenterol. 2012 Feb 28;18(8):727–35.
37. Pabst O, Hornef MW, Schaap FG, Cerovic V, Clavel T, Bruns T.
Gut-liver axis: barriers and functional circuits. Nat Rev Gastroenterol
Hepatol. 2023 Apr 21;
38. Turroni F, Ventura M, Buttó LF, Duranti S, O’Toole PW, Motherway MO,
et al. Molecular dialogue between the human gut microbiota and the host:
a Lactobacillus and Bifidobacterium perspective. Cell Mol Life Sci. 2014
Jan;71(2):183–203.
39. Su L, Zeng Y, Li G, Chen J, Chen X. Quercetin improves high-fat
diet-induced obesity by modulating gut microbiota and metabolites in
C57BL/6J mice. Phytother Res. 2022 Dec;36(12):4558–72.
40. Hoareau L, Buyse M, Festy F, Ravanan P, Gonthier MP, Matias I, et
al. Anti-inflammatory effect of palmitoylethanolamide on human
adipocytes. Obesity (Silver Spring). 2009 Mar;17(3):431–8.
41. Oyebode OA, Erukainure OL, Ibeji C, Koorbanally NA, Islam MS.
Crassocephalum rubens, a leafy vegetable, suppresses oxidative
pancreatic and hepatic injury and inhibits key enzymes linked to type 2
diabetes: An ex vivo and in silico study. J Food Biochem. 2019
Aug;43(8):e12930.